Monopar Therapeutics Inc. (MNPR)
Automate Your Wheel Strategy on MNPR
With Tiblio's Option Bot, you can configure your own wheel strategy including MNPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MNPR
- Rev/Share 0.0
- Book/Share 767.0021
- PB 0.043
- Debt/Equity 0.0
- CurrentRatio 36.9153
- ROIC -0.0604
- MktCap 201801930.0
- FreeCF/Share -81.1186
- PFCF -0.0356
- PE -0.585
- Debt/Assets 0.0
- DivYield 0
- ROE -0.2938
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MNPR | Piper Sandler | -- | Overweight | -- | $76 | March 19, 2025 |
| Initiation | MNPR | Piper Sandler | -- | Overweight | -- | $72 | Jan. 10, 2025 |
| Initiation | MNPR | Rodman & Renshaw | -- | Buy | -- | $50 | Oct. 11, 2024 |
News
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to a 51.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMETTE, Ill., June 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that it will be added to the broad-market Russell 3000® Index, with automatic inclusion in the small-cap Russell 2000® Index, after the close of U.S. equity markets on June 27, 2025.
Read More
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, is presenting today data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025, one of the most prominent global conferences in liver disease. Monopar's late-breaker poster presentation is available at the following link: https://www.monopartx.com/pipeline/ALXN1840/EASL-poster-may-2025.
Read More
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
About Monopar Therapeutics Inc. (MNPR)
- IPO Date 2019-12-19
- Website https://www.monopartx.com
- Industry Biotechnology
- CEO Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
- Employees 14